Jazz Pharmaceuticals
Jazz Pharmaceuticals

Jazz Pharmaceuticals

Pharmaceuticals
WebsiteInvestor RelationsSEC
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

$16B

Market Cap • 9/14/2026

2003

(23 years)

Founded

2007

(19 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Ireland

Ireland

Country

Valuation

P/B

3,3

P/S

3,5

P/EBITDA

9,9

P/OCF

9,6

P/FCF

10

P/E

17

BVPS

73,7

EPS

14,5

Market Cap

Market Cap

16B

EV

18,2B

EV/Revenue

3,9

EV/EBITDA

11,2

EV/EBIT

20,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,9%

Total Yield

-0,9%

Payout

0%

Retained Earnings

1,1B

Profitability

Gross Margin

88,4%

EBITDA Margin

35,1%

EBIT Margin

19,5%

Net Margin

20,5%

D&A/EBITDA

42,1%

R&D/Revenue

17,7%

Capex/Revenue

1,5%

Capex/D&A

9,7%

Capex/OCF

4,2%

SBC/OCF

18,5%

% PPE

2,4%

% Goodwill

16,2%

ROE

22,1%

ROIC

14,3%

Growth

CAGR Revenue 5Y

11,9%

CAGR Op. Income 5Y

14,2%

CAGR Net Income 5Y

92,2%

CAGR EPS 5Y

72,5%

CAGR OCF 5Y

16,6%

Leverage

N.D./EBITDA

1,4

Debt/Equity

0%

Current Ratio

1,8

Quick Ratio

1,4

Interest Coverage

524,5%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium